グラクソ・スミスクラインGSKのチャート
GSKの企業情報
| symbol | GSK |
|---|---|
| 会社名 | GlaxoSmithKline Plc （グラクソ・スミスクライン） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | グラクソ・スミスクライン（GlaxoSmithKline plc）は医療グループであり、ワクチン、市販薬（OTC）及び健康製品等の医薬品の作成、発見、開発、製造及び販売に従事する。同社は主に呼吸器、抗ウイルス、中枢神経系、心血管と泌尿生殖器、代謝、抗菌、腫瘍と嘔吐、皮膚、希少疾患、免疫・炎症、ワクチン及びヒト免疫不全ウイルス（HIV）等の治療分野向けに医薬品を提供している。同社は主に医薬品事業、ワクチン事業、およびコンシューマーヘルスケア事業の3事業区分により構成される。平成24年1月31日、同社は米国とカナダにおけるブランドをPrestige Brands Holdingsに売却完了した。同年8月、同社はHuman Genome Sciencesを買収した。平成25年1月30日、GSKは同社における持ち分の29.3％を追加買収した。 グラクソ・スミスクラインはイギリスの製薬メ―カ―。呼吸器、抗ウイルス、中枢神経、心臓血管、泌尿生殖器、がん、ワクチン、HIV分野で医療用医薬品を展開。主要製品は、鼻炎治療薬、肺疾患治療薬、抗血栓症薬、がん治療薬、抗HIV薬、ジフテリア・インフルエンザワクチンなど。オ―ラルケア製品、禁煙補助薬、市販薬、栄養補助製品などヘルスケア製品も提供。 GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. |
| 本社所在地 | 980 Great West Road Brentford Middlesex TW8 9GS GBR |
| 代表者氏名 | Emma Walmsley |
| 代表者役職名 | Chief Executive Officer Executive Director |
| 電話番号 | +44 20-8047-5000 |
| 設立年月日 | 36495 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 95490人 |
| url | www.gsk.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） 12929.04000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 103966.30000 |
| 売上高 | （百万ドル） 40178.07000 |
| 企業価値(EV) | （百万ドル） 132783.55500 |
| 当期純利益 | （百万ドル） 4885.87000 |
| 決算概要 | BRIEF: For the fiscal year ended 31 December 2018 GlaxoSmithKline plc (ADR) revenues increased 2% to ￡30.82B. Net income before extraordinary items increased 44% to ￡3.75B. Revenues reflect Vaccines segment increase of 14% to ￡5.89B US segment increase of 6% to ￡11.98B. Net income benefited from Consumer Healthcare segment income increase from ￡1.37B to ￡5.74B Unallocated segment loss decrease of 23% to ￡3.72B. Dividend per share remained flat at ￡0.80. |
GSKのテクニカル分析
GSKのニュース
Adoptive Cell Therapy Market Market will generate new growth opportunities 2023-2030 | GSK, AstraZeneca Plc, Merck, Dey. 2023/05/04 11:59:32 EIN News Pharmaceuticals
Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells are given to a patient to help the body fight diseases, such as cancer. BURLINGAME, CALIFORNIA, UNITED STATES, May 4, 2023 /EINPresswire.com/ -- Adoptive Cell Therapy Market …
Powell Says Banking System ‘Sound and Resilient.’ Try Telling That to PacWest Investors. 2023/05/04 10:39:00 Barron''s
GSK and Eli Lilly vaccines are in the spotlight, Shell beats expectations with profit of nearly $10bn, and other news to start your day.
US FDA approves GSK’s Arexvy, world’s first RSV vaccine for older adults 2023/05/04 06:32:18 Express Pharma
Older adults, including those with underlying medical conditions such as diabetes and chronic heart and lung disease, are at increased risk of severe RSV illness The post US FDA approves GSK’s Arexvy, world’s first RSV vaccine for older adults appeared first on Express Pharma .
US approves GSK’s Arexvy, the world’s first RSV vaccine for older adults 2023/05/04 05:15:57 Firstpost
US approves GSK’s Arexvy, the world’s first RSV vaccine for older adults
FDA Approves GSK''s Arexvy, World''s First RSV Vaccine For Older Adults 2023/05/04 02:48:00 Finanz Nachrichten
LONDON (dpa-AFX) - The U.S. Food and Drug Administration approved GSK Plc.''s (GSK.L, GSK) Arexvy, the world''s first respiratory syncytial virus or RSV vaccine for older adults.Arexvy is approved f…
New MRGPRX2 antagonists identified at GlaxoSmithKline 2022/05/04 13:58:12 BioWorld
Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more
GSK’s £45bn Panadol and Sensodyne-maker Haleon in talks to hire banks 2022/05/03 17:46:00 Sky News
The £45bn company that will be created from the demerger of GlaxoSmithKline’s (GSK) consumer products arm is in talks to hire a roster of investment bankers in one of the year’s most prestigious City pitches.
Swiss scientist convicted of scheme to steal GSK trade secrets 2022/05/02 17:24:40 Reuters
A Swiss scientist has been convicted on charges that he conspired with his sister to steal trade secrets from the drugmaker GlaxoSmithKline to benefit biopharmaceutical companies they established, including one the Chinese government financed.
GSK, SK bioscience seek approval of COVID vaccine SKYCovione in South Korea, after beating AstraZeneca''s Vaxzevria in trial 2022/04/29 09:50:28 Seeking Alpha
GlaxoSmithKline (GSK) and SK bioscience submitted a biologics license application to the Korean Ministry of Food and Drug Safety ((KMFDS)) seeking approval of SKYCovione, following…
GSK and SK bioscience’s COVID vaccine submitted for S.Korea approval 2022/04/29 07:55:50 Financial Post
GlaxoSmithKline’s (GSK) COVID-19 vaccine candidate developed with SK bioscience has been submitted for regulatory approval in South Korea after positive positive Phase III clinical data, the British drugmaker said on Friday. GSK said that SK bioscience will also apply to the World Health Organization (WHO) for emergency use listing and seek authorisations at individual regulatory […]
Glaxosmithkline plc - ADR Shares Climb 0.7% Past Previous 52-Week High - Market Mover 2021/12/30 00:54:54 Kwhen Finance
Glaxosmithkline plc - ADR (GSK) shares closed 0.7% higher than its previous 52 week high, giving the company a market cap of $110B. The stock is currently up 26.8% year-to-date, up 28.6% over the past 12 months, and up 50.1% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 42.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -36.1% The company's stock price performance over the past 12 months lags the peer average by -26.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.7% lower than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Glaxosmithkline plc - ADR Shares Approach 52-Week High - Market Mover 2021/12/27 09:32:55 Kwhen Finance
Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 28.1% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 21.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -20.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Glaxosmithkline plc - ADR Shares Close in on 52-Week High - Market Mover 2021/12/26 09:42:21 Kwhen Finance
Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 28.1% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 20.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -20.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Glaxosmithkline plc - ADR Shares Approach 52-Week High - Market Mover 2021/12/24 23:01:37 Kwhen Finance
Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 27.8% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 1.2%. Trading Activity Trading volume this week was 20.7% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -16.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Global Autoimmune Disorder Drug Delivery Device Market Is Predicted To Propel Owing To Surging Adoption Of Advanced Drug Delivery Devices: Ken Research 2021/12/24 14:35:24 Ken Research
Buy Now According to the report analysis, Global Autoimmune Disorder Drug Delivery Device Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027 states that AbbVie Inc., Bayer AG, Novartis AG, Amgen Inc., Merck KGaA, F. Hoffmann- La Roche Ltd., Teva Pharmaceutical Industries Ltd., Biogen Inc., GlaxoSmithKline Plc, Johnson Read More » The post Global Autoimmune Disorder Drug Delivery Device Market Is Predicted To Propel Owing To Surging Adoption Of Advanced Drug Delivery Devices: Ken Research appeared first on Ken Research .